- Stocks
- Pharma & Healthcare
- Caplin Point Laboratories
Caplin Point Laboratories share price
NSE: CAPLIPOINTPharma & Healthcare
Caplin Point Laboratories at a glance
Caplin Point Laboratories (NSE: CAPLIPOINT) closed at ₹2,227.80 on 22 Oct 2026, up 0.35% on the day. With a market capitalisation of ₹16,934 Cr, it ranks 388th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
Its return on equity was 19.3% in FY25. Over the past year the share price has risen 12.9%. Its 52-week range is ₹1,500.30 (30 Mar 2026) to ₹2,990.00 (24 Sep 2026); the last close is 25.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹600 Cr (+19.4% year on year) and net profit ₹173 Cr (+19.1%), on a consolidated basis. Promoters held 70.57% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹16,934 CrRank 388 on NSE
- Price to book
- 5.48×FY25
- EPS (TTM)
- ₹84.36to Q4 FY26
- ROE
- 19.3%FY25
- ROCE
- 23.3%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 27.9%FY25
- Book value / share
- ₹365.25FY25
- 52-week high
- ₹2,990.0024 Sep 2026
- 52-week low
- ₹1,500.3030 Mar 2026
- 1-year return
- +12.9%
- RSI (14-day)
- 27.6
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.35% | −4.7% | −19.7% | −10.6% | +12.9% |
Caplin Point Laboratories quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹459 Cr | ₹483 Cr | ₹493 Cr | ₹502 Cr | ₹510 Cr | ₹534 Cr | ₹543 Cr | ₹600 Cr |
| Revenue YoY | +16.1% | +17.8% | +13.2% | +10.9% | +11.2% | +10.5% | +10.1% | +19.4% |
| Net profit | ₹125 Cr | ₹131 Cr | ₹140 Cr | ₹145 Cr | ₹151 Cr | ₹160 Cr | ₹166 Cr | ₹173 Cr |
| Net profit YoY | +19.9% | +12.8% | +16.9% | +19.8% | +20.7% | +22.4% | +18.4% | +19.1% |
| Net margin | 27.2% | 27.1% | 28.4% | 28.9% | 29.5% | 30.0% | 30.6% | 28.8% |
| EPS | ₹16.32 | ₹17.22 | ₹18.28 | ₹18.75 | ₹20.10 | ₹20.32 | ₹21.56 | ₹22.38 |
Caplin Point Laboratories financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹863 Cr | ₹1,061 Cr | ₹1,269 Cr | ₹1,467 Cr | ₹1,694 Cr | ₹1,937 Cr |
| Operating profit | ₹269 Cr | ₹314 Cr | ₹386 Cr | ₹451 Cr | ₹564 Cr | ₹677 Cr |
| Net profit | ₹215 Cr | ₹251 Cr | ₹308 Cr | ₹377 Cr | ₹461 Cr | ₹541 Cr |
| EPS (₹) | ₹28.00 | ₹32.00 | ₹40.00 | ₹50.00 | ₹60.00 | ₹71.00 |
| Cash from operations | ₹45 Cr | ₹266 Cr | ₹337 Cr | ₹271 Cr | ₹318 Cr | ₹432 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹873 Cr | ₹1,186 Cr | ₹1,409 Cr | ₹1,806 Cr | ₹2,241 Cr | ₹2,776 Cr |
Caplin Point Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.56% | 70.56% | 70.57% | 70.57% | 70.57% | 70.57% |
| Foreign institutions | 5.73% | 6.17% | 6.51% | 6.59% | 6.15% | 5.75% |
| Domestic institutions | 2.01% | 2.22% | 2.10% | 2.05% | 2.14% | 2.49% |
| Non-institutions | 21.70% | 21.05% | 20.82% | 20.79% | 21.14% | 21.18% |
Caplin Point Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Caplin Point Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| COHANCECohance Lifesciences | ₹460.30 | −0.25% | −46.9% | ₹17,610 Cr | 98.6 | — |
| SHILPAMEDShilpa Medicare | ₹880.90 | +4.74% | +150.3% | ₹17,229 Cr | 70.9 | — |
| PFIZERPfizer | ₹3,712.10 | −0.93% | −30.9% | ₹16,982 Cr | 23.5 | — |
| CAPLIPOINTCaplin Point Laboratories | ₹2,227.80 | +0.35% | +12.9% | ₹16,934 Cr | — | — |
| ERISEris Lifesciences | ₹1,143.60 | +0.76% | −27.9% | ₹15,848 Cr | 25.3 | — |
| ONESOURCEOnesource Specialty Pharma | ₹1,378.00 | +1.64% | −25.1% | ₹15,798 Cr | — | — |
| ALIVUSAlivus Life Sciences | ₹1,272.00 | +0.82% | +37.5% | ₹15,612 Cr | 27.7 | — |
Ask anything about Caplin Point Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against CAPLIPOINT's own history. Try: “Why has CAPLIPOINT moved over the last three months?” · “Backtest a 50-day moving-average crossover on CAPLIPOINT over five years” · “Compare CAPLIPOINT with COHANCE on margins and valuation”
Frequently asked questions about Caplin Point Laboratories
What is the share price of Caplin Point Laboratories today?
Caplin Point Laboratories (NSE: CAPLIPOINT) last closed at ₹2,227.80 on 22 Oct 2026. Its 52-week high is ₹2,990.00 and its 52-week low is ₹1,500.30.
What is the market cap of Caplin Point Laboratories?
Caplin Point Laboratories' market capitalisation is ₹16,934 Cr (₹16,934 Cr) at the 22 Oct 2026 close, ranking 388th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Caplin Point Laboratories?
Return on equity was 19.3% in FY25 and return on capital employed was 23.3% in FY25 (consolidated figures).
Is Caplin Point Laboratories a debt-free company?
Caplin Point Laboratories is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Caplin Point Laboratories' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Caplin Point Laboratories reported revenue of ₹600 Cr, +19.4% year on year, and net profit of ₹173 Cr, +19.1% year on year.
How has Caplin Point Laboratories stock performed over the last year?
Caplin Point Laboratories' share price has risen 12.9% over the past year, −10.6% over three months and −19.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Caplin Point Laboratories?
As of 30 Jun 2026: promoters 70.57%, foreign institutions 5.75%, domestic institutions 2.49%, non-institutions 21.18%.
Who are Caplin Point Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Caplin Point Laboratories by market cap are Cohance Lifesciences, Shilpa Medicare, Pfizer, Eris Lifesciences, Onesource Specialty Pharma and Alivus Life Sciences.
Is Caplin Point Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Caplin Point Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CAPLIPOINT against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text